Published • loading... • Updated
FDA Allows Public Comments on Moderna’s New mRNA Influenza ‘Pandemic’ Vaccine MFLUSIVA (mRNA-1010)
Summary by sgtreport.com
Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.1 Articles
1 Articles
FDA Allows Public Comments on Moderna’s New mRNA Influenza ‘Pandemic’ Vaccine MFLUSIVA (mRNA-1010)
by Jon Fleetwood, Jon Fleetwood: MFLUSIVA triggers six times more severe reactions for less than 1% absolute benefit, Moderna scientists admitted last month in the New England Journal of Medicine. The U.S. Food and Drug Administration (FDA) has scheduled a June 18, 2026 advisory committee meeting to publicly review the “safety and effectiveness” of Moderna’s […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right1Center0Last UpdatedBias Distribution100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium
